BioCentury | Feb 2, 2018
Company News
Shire licenses recombinant immunoglobulin from AB Biosciences
...and commercialize its pan receptor interacting molecule (PRIM) program. PRIM is a recombinant immunoglobulin that AB Biosciences...
...in preclinical models of autoimmune and inflammatory diseases compared with approved IV immunoglobulin (IVIG) therapies. AB Biosciences...
...9, 2014 ). AB Biosciences Inc., Allston, Mass. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Autoimmune, Inflammation Chris Lieu AB Biosciences Inc. Shire...
...in preclinical models of autoimmune and inflammatory diseases compared with approved IV immunoglobulin (IVIG) therapies. AB Biosciences...
...9, 2014 ). AB Biosciences Inc., Allston, Mass. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Autoimmune, Inflammation Chris Lieu AB Biosciences Inc. Shire...